The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > REGULATORY
REGULATORY
- Conclusion of TPP Talks over IP Rights Postponed
October 29, 2013
- Kenporen Calls for Taking 6 APIs Over the Counter
October 29, 2013
- LDP Establishes Study Group on Pharmaceutical Industry Policy; 11 Domestic Drug Makers to Participate
October 28, 2013
- TPP IP Talks Kick Off in Tokyo, Government Task Force to Hold Press Conference on Oct 28
October 25, 2013
- Regulatory Reform Council to Convene Public Discussion on Expansion of “Mixed Healthcare” on November 28
October 25, 2013
- Diovan Panel Should Question 4 Key Figures to Dig into Scandal Further: Expert Member
October 24, 2013
- Lawmakers Concerned over Effects of Diovan Papers on Public Finances for Health Insurance
October 24, 2013
- Probable Price Settlement Rate of Lower 70% Range “Disappointing”: MHLW’s Economic Affairs Head Jo
October 24, 2013
- PFSB Notification Calls for Revisions to Precautions Sections of Package Inserts for Olmesartan and Other Drugs
October 24, 2013
- MOF Demands Hefty Price Cuts for Long-Listed Products, Skeptical about Premium
October 23, 2013
- Govt Task Force Briefs Trade Groups on Tokyo’s Hosting of TPP Interim Talks on IP
October 23, 2013
- Basic Policy Calls for Wider Range of Uninsured Healthcare Services in National Strategic Special Zones
October 23, 2013
- Expert Panel Calls for Measures to Promote Commercialization of Results of Basic Research in Field of Healthcare
October 23, 2013
- DPJ Nagatsuma Requests Summoning Novartis President and Former Employee for Unsworn Diet Testimony
October 22, 2013
- Avastin to Receive Additional Indication for Ovarian Cancer: PAFSC’s Second Committee on Drugs
October 22, 2013
- Vaccine Policy Committee Agrees on Draft of Basic Vaccination Plan
October 22, 2013
- 72 Face-to-Face Consultations Provided from July 2011 through September 2013: PMDA
October 21, 2013
- Ex-Health Minister Nagatsuma Eyes Unsworn Diet Testimony by Ex-Novartis Employee on Diovan Scandal
October 18, 2013
- CSIMC’s Bill Payer, Industry Reps at Odds over Objective of Premium; “Elimination of Drug Lag” vs. “New Drug Development”
October 18, 2013
- 1st Committee on Drugs to Discuss Approval for JT’s Hyperphosphatemia Treatment on October 28
October 18, 2013
ページ
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…